Bill Ackman's Latest Moves In HealthCare, And Some Of His Other Positions From Q1

Loading...
Loading...

Bill Ackman’s Pershing Square Capital Management’s equity portfolio continues to be highly concentrated, comprising only eight stocks. According to its latest 13F filing, the portfolio is focused on healthcare stocks (46 percent) and, to a lesser extent, on materials (31 percent) and transports (19 percent), and is worth approximately $14.97 billion in the market, down from $16 billion in the previous quarter.

The fund started two new positions over the first quarter of 2015.

One in Valeant Pharmaceuticals Intl Inc VRX, comprising 19,473,933 shares Common Stock. Valued at $3.86 billion, it is Pershing’s most appreciated position, accounting for more than one fourth of its total equity portfolio.

The other stake Mr. Ackman initiated over the quarter is the one at Actavis plc ACT, which contains 1,348,358 shares of the company. Actavis acquired Allergan, Inc. AGNin mid-March. So, Pershing sold most of its 26,635,978 Allegan shares. The fund held $5.66 billion in Allergan stock by the end of the fourth quarter of 2014, and now owns slightly more than $400 million in Actavis shares.

The only other company that saw any changes in Pershing’s stake is Zoetis Inc ZTS. The veterinary drugs business saw the fund acquire 253,499 shares of Class A stock between January and March, inclusive, taking its position to 41,823,145 shares, worth more than $1.9 billion.

Other stocks the fund is bullish on are Air Products & Chemicals, Inc. APD and Canadian Pacific Railway Limited (USA) CP. These stakes remained unchanged over the quarter, and account for 20.77 percent and 17 percent of Pershing’s portfolio, respectively. The firm disclosed ownership of 20,549,076 shares of Air Products & Chemicals, and 13,940,890 shares of Canadian Pacific Railway.

Loading...
Loading...
Posted In: Long IdeasHealth CareHedge FundsTrading IdeasGeneralBill AckmanPershing Square
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...